Literature DB >> 31746939

Familial hypercholesterolaemia and its management in South Africa.

A D Marais1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31746939      PMCID： PMC8802364          DOI： 10.5830/CVJA-2019-054

Source DB:  PubMed          Journal:  Cardiovasc J Afr        ISSN： 1015-9657            Impact factor:   1.167


× No keyword cloud information.
  8 in total

1.  Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.

Authors:  Philippa J Talmud; Sonia Shah; Ros Whittall; Marta Futema; Philip Howard; Jackie A Cooper; Seamus C Harrison; Kawah Li; Fotios Drenos; Frederik Karpe; H Andrew W Neil; Olivier S Descamps; Claudia Langenberg; Nicholas Lench; Mika Kivimaki; John Whittaker; Aroon D Hingorani; Meena Kumari; Steve E Humphries
Journal:  Lancet       Date:  2013-02-22       Impact factor: 79.321

2.  South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA).

Authors:  E Klug; F J Raal; A D Marais; C M Smuts; C Schamroth; D Jankelow; D J Blom; D A Webb
Journal:  S Afr Med J       Date:  2018-10-26

3.  Familial hypercholesterolaemia: the Cape Town experience.

Authors:  Jean C Firth; A David Marais
Journal:  S Afr Med J       Date:  2008-02

4.  Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.

Authors:  Merel L Hartgers; Joost Besseling; Erik S Stroes; Janneke Wittekoek; Joost H W Rutten; Jacqueline de Graaf; Frank L J Visseren; Ben P M Imholz; Jeanine E Roeters van Lennep; Roeland Huijgen; John J P Kastelein; G Kees Hovingh
Journal:  J Clin Lipidol       Date:  2018-04-18       Impact factor: 4.766

5.  Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease.

Authors:  I U Haq; P R Jackson; W W Yeo; L E Ramsay
Journal:  Lancet       Date:  1995-12-02       Impact factor: 79.321

6.  Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study.

Authors:  Dirk J Blom; Johannes Breedt; Lesley J Burgess; Iftikhar O Ebrahim; Graham Ellis; Prashilla Soma; Eugene van der Walt; Poobalan Naidoo; Alet van Tonder; Frederick J Raal
Journal:  Cardiovasc J Afr       Date:  2019-09-11       Impact factor: 1.167

7.  Familial hypercholesterolaemia workshop for leveraging point-of-care testing and personalised medicine in association with the Lipid and Atherosclerosis Society of Southern Africa.

Authors:  A D Marais; M J Kotze; F J Raal; A A Khine; P J Talmud; S E Humphries
Journal:  Cardiovasc J Afr       Date:  2019 Sep/Oct       Impact factor: 1.167

Review 8.  Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

Authors:  Raul D Santos; Samuel S Gidding; Robert A Hegele; Marina A Cuchel; Philip J Barter; Gerald F Watts; Seth J Baum; Alberico L Catapano; M John Chapman; Joep C Defesche; Emanuela Folco; Tomas Freiberger; Jacques Genest; G Kees Hovingh; Mariko Harada-Shiba; Steve E Humphries; Ann S Jackson; Pedro Mata; Patrick M Moriarty; Frederick J Raal; Khalid Al-Rasadi; Kausik K Ray; Zelijko Reiner; Eric J G Sijbrands; Shizuya Yamashita
Journal:  Lancet Diabetes Endocrinol       Date:  2016-05-27       Impact factor: 32.069
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.